Induction of TNF-alpha, uPA, IL-8 and MCP-1 by doxorubicin in human lung carcinoma cells

Cancer Chemother Pharmacol. 2003 Nov;52(5):391-8. doi: 10.1007/s00280-003-0665-1. Epub 2003 Aug 8.

Abstract

Purpose: We have previously demonstrated doxorubicin-induced urokinase (uPA) and interleukin-8 (IL-8) expression in human H69 small-cell lung carcinoma (SCLC) cells by a microarray technique using Human Cancer Chip version 2, in which 425 human "cancer-related" genes are spotted on the plates. The microarray analysis also revealed a significant induction of tumor necrosis factor-alpha (TNF-alpha), and doxorubicin-induced macrophage chemoattractant protein-1 (MCP-1) expression was demonstrated by an RNase protection assay. We extended the study by testing the effects of doxorubicin on the induction of TNF-alpha, uPA, IL-8 and MCP-1 in other types of lung carcinoma cells.

Methods: We investigated the effects of doxorubicin on the expression of TNF-alpha, uPA, IL-8 and MCP-1 in 12 human lung carcinoma cell lines, including five SCLC, three adenocarcinoma and four squamous cell carcinoma cells. The surface expression of their receptors was also investigated.

Results: TNF-alpha was significantly induced in three cell lines, H69, SBC-7 (SCLC) and PC-9 (adenocarcinoma), uPA in five cell lines, H69, SBC-7, EBC-1 (squamous cell), EBC-2 (squamous cell), and Sq-1 (squamous cell), IL-8 in three cell lines, H69, PC-9 and EBC-1, and MCP-1 in five cell lines, H69, SBC-3 (SCLC), SBC-7, PC-9 and Sq-1. In H69 cells, TNF-alpha antigen levels were increased approximately fivefold in the conditioned medium of doxorubicin-treated cells, in parallel with an increase in mRNA levels. As with uPA and IL-8, the maximum induction was observed at the "sublethal" concentrations of 2 and 4 microM at which cell growth was slightly inhibited 24 h after treatment. Furthermore, the cells did not express receptors including types I and II TNF-alpha receptors, uPA receptor (uPAR), C-x-C-chemokine receptor-1 (CXCR-1), or C-C-chemokine receptor-2, corresponding to TNF-alpha, uPA, IL-8 and MCP-1, respectively, that were induced by doxorubicin in the cells, although SBC-7 cells expressed uPAR, and EBC-1 cells expressed CXCR-1.

Conclusions: TNF-alpha, uPA, IL-8 and MCP-1 induced and secreted from tumor cells upon doxorubicin stimulation may activate surrounding cells expressing the receptors such as neutrophils and monocytes/macrophages in a paracrine fashion. TNF-alpha is a major proinflammatory cytokine, and IL-8 and MCP-1 are major chemoattractants for neutrophils and monocytes/macrophages, respectively. Furthermore, uPA activates matrix metalloproteinase 9 which can truncate and activate IL-8. Thus, the simultaneous induction of TNF-alpha, uPA, IL-8 and MCP-1 may enhance the interaction between tumor and inflammatory/immune cells, and augment cytotoxicity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibiotics, Antineoplastic / pharmacology*
  • Antigens, CD / biosynthesis
  • Blotting, Northern
  • Carcinoma, Non-Small-Cell Lung / metabolism
  • Cell Line, Tumor
  • Chemokine CCL2 / biosynthesis*
  • Doxorubicin / pharmacology*
  • Flow Cytometry
  • Humans
  • Interleukin-8 / biosynthesis*
  • Lung Neoplasms / metabolism*
  • Monocytes / metabolism
  • Neutrophils / metabolism
  • Oligonucleotide Array Sequence Analysis
  • Receptors, CCR2
  • Receptors, Cell Surface / biosynthesis
  • Receptors, Chemokine / biosynthesis
  • Receptors, Interleukin-8A / biosynthesis
  • Receptors, Tumor Necrosis Factor / biosynthesis
  • Receptors, Tumor Necrosis Factor, Type I
  • Receptors, Tumor Necrosis Factor, Type II
  • Receptors, Urokinase Plasminogen Activator
  • Tumor Necrosis Factor-alpha / biosynthesis*
  • Urokinase-Type Plasminogen Activator / biosynthesis*

Substances

  • Antibiotics, Antineoplastic
  • Antigens, CD
  • CCR2 protein, human
  • Chemokine CCL2
  • Interleukin-8
  • PLAUR protein, human
  • Receptors, CCR2
  • Receptors, Cell Surface
  • Receptors, Chemokine
  • Receptors, Interleukin-8A
  • Receptors, Tumor Necrosis Factor
  • Receptors, Tumor Necrosis Factor, Type I
  • Receptors, Tumor Necrosis Factor, Type II
  • Receptors, Urokinase Plasminogen Activator
  • Tumor Necrosis Factor-alpha
  • Doxorubicin
  • Urokinase-Type Plasminogen Activator